Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report observed alopecia universalis, a complete hair loss condition, in a patient during a clinical trial with the angiotensin receptor-neprilysin inhibitor sacubitril/alisartan, indicating that ARNI therapy might be associated with such cutaneous reactions.

This review discusses advancements in the use of microneedle arrays and nanoparticles for transdermal delivery of therapeutics, noting challenges in overcoming the skin barrier and summarizing recent clinical trial achievements in areas like cancer therapy and gene therapy.

This study found significant associations between PCOS susceptibility and specific genetic variants in the APOA5 and PLIN1 genes among Western Saudi women, identifying novel alleles and genotypes that may influence PCOS risk and related clinical characteristics.

Losartan can cause temporary loss of taste.

This case report details a woman with postural orthostatic tachycardia syndrome who experienced notable dermatological symptoms, including evanescent hyperemia, which improved with the use of an oral angiotensin II type 1 receptor antagonist.

This study found that epidermal Wnt production is crucial for forming the skin's spinous layer through a BMP-FGF signaling cascade, although Wnt from basal cells is not needed for their differentiation.

This study demonstrated that a new topical treatment using ketotifen-loaded microneedles, designed for prolonged release, significantly reduced inflammatory markers in an animal model of allergic conjunctivitis, suggesting enhanced therapeutic delivery and sustained ocular benefits.

Finasteride safely treats enlarged prostate and male-pattern baldness.

This study found that while participants in Jeddah, Saudi Arabia, had good knowledge about Vitamin D and recognized sunlight as a key source, there was inconsistency in their attitudes towards maintaining adequate Vitamin D levels.

This review in SEDA Volume 40 summarizes new adverse reaction data for diuretics published in 2017, highlighting specific risks such as fractures with loop diuretics and hyperkalemia with spironolactone.

This review discusses the integration of nanoparticles with microneedles to improve drug delivery through enhanced stability, bioavailability, and controlled release, noting ongoing challenges with stability, scalability, and safety.

This review provides an overview of microneedle-assisted photomedicine, detailing diagnostic and therapeutic strategies, design principles, and challenges for translating this approach to skin disease management.

This review highlights the potential of microneedle devices in dermatology for conditions like skin aging and autoimmune skin diseases, emphasizing their ability to facilitate targeted drug delivery by creating temporary skin pathways.

This study used computational methods to identify pranlukast and mirabegron as promising candidates for repurposing against diabetes due to their good binding interactions with the DPP-IV target.

This review discusses the formulations, mechanisms, and physiological aspects of hair cosmetics and types, but reports no new results, suggesting a foundation for future hair research.

In this study, exposure to ARBs, ACE inhibitors, and thiazides was associated with an increased risk of various skin cancers, including melanoma and nonmelanoma types, highlighting potential clinical implications for antihypertensive treatment choices.

This study found that artocarpin delivered via alginate/chitosan microparticles effectively suppressed the growth of hamster flank organs compared to artocarpin in solution form, without significant systemic effects.

This case report suggests that lisinopril may cause alopecia, which resolved after the patient switched to losartan potassium.

This reference compilation details potential adverse skin reactions and other side effects associated with the antihypertensive drug Quinazil, including rare cases of skin angioedema and other dermatological reactions.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

In this study, researchers investigated the effects of Aqueous Artocarpus heterophyllus seed extract on testosterone enanthate-induced benign prostatic hyperplasia in adult Wistar rats, using three different dosages to assess its potential as an alternative therapy. Results are not reported in this abstract.

In this study, daily treatment with angiotensin (1-7) significantly reduced disease severity in a mouse model of Systemic Lupus Erythematosus, suggesting potential for Mas agonists in future therapies.

In this study, dihydroartemisinin reduced prostate enlargement and related markers in a rat model of benign prostatic hyperplasia, suggesting its potential as a therapeutic agent.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This study evaluated the potential toxicity of oral dihydroartemisinin in SD rats, finding that female rats experienced greater toxic effects than males, particularly at higher doses, but these effects were reversible after a 4-week recovery period.

This study identified neprilysin as a potential target of the pharmacological agent arteannuin, which may guide future research into its clinical applications, although experimental verification is needed.

This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

In this analysis of the BRAVE-AA trials, a significant number of patients with severe alopecia areata treated with baricitinib reached complete or nearly complete scalp coverage (SALT score ≤10 or ≤5) over 52 weeks, particularly among those with less severe baseline characteristics.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.